X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs SUN PHARMA - Comparison Results

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA SUN PHARMA NATCO PHARMA/
SUN PHARMA
 
P/E (TTM) x 13.5 34.4 39.2% View Chart
P/BV x 3.9 2.7 144.5% View Chart
Dividend Yield % 1.2 0.5 244.2%  

Financials

 NATCO PHARMA   SUN PHARMA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-18
SUN PHARMA
Mar-18
NATCO PHARMA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,080701 154.2%   
Low Rs671433 155.0%   
Sales per share (Unadj.) Rs592.1110.4 536.3%  
Earnings per share (Unadj.) Rs188.411.0 1,716.2%  
Cash flow per share (Unadj.) Rs206.317.2 1,197.7%  
Dividends per share (Unadj.) Rs8.252.00 412.5%  
Dividend yield (eoy) %0.90.4 267.0%  
Book value per share (Unadj.) Rs833.6158.8 524.9%  
Shares outstanding (eoy) m36.902,399.26 1.5%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x1.55.1 28.8%   
Avg P/E ratio x4.651.6 9.0%  
P/CF ratio (eoy) x4.232.9 12.9%  
Price / Book Value ratio x1.13.6 29.4%  
Dividend payout %4.418.2 24.0%   
Avg Mkt Cap Rs m32,3111,360,021 2.4%   
No. of employees `0004.817.8 27.2%   
Total wages/salary Rs m3,25653,671 6.1%   
Avg. sales/employee Rs Th4,522.514,890.9 30.4%   
Avg. wages/employee Rs Th674.03,017.1 22.3%   
Avg. net profit/employee Rs Th1,439.01,480.6 97.2%   
INCOME DATA
Net Sales Rs m21,848264,895 8.2%  
Other income Rs m4048,388 4.8%   
Total revenues Rs m22,252273,282 8.1%   
Gross profit Rs m9,28456,081 16.6%  
Depreciation Rs m66214,998 4.4%   
Interest Rs m1545,176 3.0%   
Profit before tax Rs m8,87244,295 20.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-9,505 0.0%   
Tax Rs m1,9208,452 22.7%   
Profit after tax Rs m6,95226,338 26.4%  
Gross profit margin %42.521.2 200.7%  
Effective tax rate %21.619.1 113.4%   
Net profit margin %31.89.9 320.0%  
BALANCE SHEET DATA
Current assets Rs m21,307316,359 6.7%   
Current liabilities Rs m5,920198,643 3.0%   
Net working cap to sales %70.444.4 158.5%  
Current ratio x3.61.6 226.0%  
Inventory Days Days7395 77.3%  
Debtors Days Days107108 98.9%  
Net fixed assets Rs m14,986213,178 7.0%   
Share capital Rs m3692,399 15.4%   
"Free" reserves Rs m30,353378,606 8.0%   
Net worth Rs m30,760381,006 8.1%   
Long term debt Rs m017,721 0.0%   
Total assets Rs m37,151643,028 5.8%  
Interest coverage x58.69.6 613.2%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.60.4 142.8%   
Return on assets %19.14.9 390.3%  
Return on equity %22.66.9 326.9%  
Return on capital %29.310.0 292.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m10,32240,816 25.3%   
Fx outflow Rs m2,97830,143 9.9%   
Net fx Rs m7,34310,673 68.8%   
CASH FLOW
From Operations Rs m4,63639,072 11.9%  
From Investments Rs m-11,155-33,708 33.1%  
From Financial Activity Rs m6,509-15,393 -42.3%  
Net Cashflow Rs m-18-7,359 0.2%  

Share Holding

Indian Promoters % 52.0 63.7 81.7%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 5.1 152.8%  
FIIs % 16.6 23.0 72.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 8.3 313.3%  
Shareholders   25,395 133,026 19.1%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   STERLING BIOTECH  PFIZER  ALEMBIC PHARMA  ORCHID PHARMA LTD  SANOFI INDIA  

Compare NATCO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 150 Points Higher; Banking Stocks Witness Buying(Closing)

Indian share markets continued their momentum and ended the day on a positive note. Gains were largely seen in the banking sector, consumer durables sector and realty sector.

Related Views on News

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 115.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 115.2% YoY). Sales on the other hand came in at Rs 5 bn (up 27.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Dec 13, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS